Long-Term Data: TransCon PTH Sustains Efficacy for 5 Years in Hypoparathyroidism
ASND sits 34% above its 52-week low of $160.86.
Summary
Ascendis Pharma announced positive 5-year data from its Phase 2 PaTH Forward Trial for TransCon PTH (YORVIPATH) in adults with hypoparathyroidism. The results demonstrated sustained efficacy and safety, with 82% of patients achieving the primary multi-component endpoint, including normal serum calcium and independence from conventional therapy. This long-term data for an already approved and revenue-generating drug significantly reinforces its market position and potential as a standard of care. It provides strong validation for the drug's continued commercial success and long-term revenue potential.
At the time of this announcement, ASND was trading at $215.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.4B. The 52-week trading range was $160.86 to $250.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.